Screener
Krystal Biotech, Inc. KRYS Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $4,089 | $3,238 |
| Current portion of lease liability | 1,800 | 1,771 |
| Accrued rebates | 70,717 | 58,181 |
| Accrued expenses and other current liabilities | 31,196 | 39,752 |
| Total current liabilities | 107,802 | 102,942 |
| Lease liability | 7,312 | 7,568 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s operating lease liabilities (current)?
- Krystal Biotech, Inc. (KRYS) reported operating lease liabilities (current) of $1.8M in Q1 2026.
- How has Krystal Biotech, Inc.'s operating lease liabilities (current) changed year-over-year?
- Krystal Biotech, Inc.'s operating lease liabilities (current) increased by 32.2% year-over-year, from $1.36M to $1.8M.
- What is the long-term trend for Krystal Biotech, Inc.'s operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s operating lease liabilities (current) has grown at a -19.1% compound annual growth rate (CAGR), from $5.11M to $1.77M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Krystal Biotech, Inc.'s operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude